113 related articles for article (PubMed ID: 25040195)
1. Central nervous system prophylaxis in patients with diffuse large B cell lymphoma, are we treating ourselves? A response to the recent BCSH Guideline - response to Griffin et al.
McMillan A; Ardeshna KM; Cwynarski K; Lyttelton M; McKay P; Montoto S
Br J Haematol; 2014 Nov; 167(4):579-80. PubMed ID: 25040195
[No Abstract] [Full Text] [Related]
2. Central nervous system prophylaxis in patients with diffuse large B cell lymphoma, are we treating ourselves? A response to the recent BCSH Guideline.
Griffin M; Goddard K; Morley N; Went R; Fletcher A; Wright J
Br J Haematol; 2014 Nov; 167(4):577-9. PubMed ID: 24909921
[No Abstract] [Full Text] [Related]
3. Secondary central nervous system lymphoma: risk factors and prophylaxis.
Montoto S; Lister TA
Hematol Oncol Clin North Am; 2005 Aug; 19(4):751-63, viii. PubMed ID: 16083835
[TBL] [Abstract][Full Text] [Related]
4. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology.
McMillan A; Ardeshna KM; Cwynarski K; Lyttelton M; McKay P; Montoto S;
Br J Haematol; 2013 Oct; 163(2):168-81. PubMed ID: 24033102
[TBL] [Abstract][Full Text] [Related]
5. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
O'Rourke K; Morris K; Kennedy GA
Cancer; 2011 Jun; 117(11):2579-80; author reply 2580-1. PubMed ID: 24048807
[No Abstract] [Full Text] [Related]
6. Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?
Cheah CY; Seymour JF
Curr Oncol Rep; 2015 Jun; 17(6):25. PubMed ID: 25912004
[TBL] [Abstract][Full Text] [Related]
7. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
8. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK.
Cheung CW; Burton C; Smith P; Linch DC; Hoskin PJ; Ardeshna KM
Br J Haematol; 2005 Oct; 131(2):193-200. PubMed ID: 16197449
[TBL] [Abstract][Full Text] [Related]
10. Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature.
Colocci N; Glantz M; Recht L
Semin Neurol; 2004 Dec; 24(4):395-404. PubMed ID: 15637651
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system prophylaxis in diffuse large B-cell lymphoma.
Zahid MF; Khan N; Hashmi SK; Kizilbash SH; Barta SK
Eur J Haematol; 2016 Aug; 97(2):108-20. PubMed ID: 27096423
[TBL] [Abstract][Full Text] [Related]
12. How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis.
Hall KH; Panjic EH; Valla K; Flowers CR; Cohen JB
Oncology (Williston Park); 2018 Jun; 32(6):303-9. PubMed ID: 29940062
[TBL] [Abstract][Full Text] [Related]
13. To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin's lymphoma.
Lim HY; Thiel E; Glantz MJ
Curr Opin Oncol; 2008 Sep; 20(5):495-501. PubMed ID: 19106650
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.
Ghose A; Kundu R; Latif T
Crit Rev Oncol Hematol; 2014 Sep; 91(3):292-303. PubMed ID: 24698003
[TBL] [Abstract][Full Text] [Related]
15. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
Kumar A; Vanderplas A; LaCasce AS; Rodriguez MA; Crosby AL; Lepisto E; Czuczman MS; Nademanee A; Niland J; Gordon LI; Millenson M; Zelenetz AD; Friedberg JW; Abel GA
Cancer; 2012 Jun; 118(11):2944-51. PubMed ID: 22006274
[TBL] [Abstract][Full Text] [Related]
16. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
17. Treatment and prevention of secondary CNS lymphoma.
Nagpal S; Glantz MJ; Recht L
Semin Neurol; 2010 Jul; 30(3):263-72. PubMed ID: 20577933
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
[TBL] [Abstract][Full Text] [Related]
19. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511
[TBL] [Abstract][Full Text] [Related]
20. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.
Herrlinger U; Glantz M; Schlegel U; Gisselbrecht C; Cavalli F
Semin Oncol; 2009 Aug; 36(4 Suppl 2):S25-34. PubMed ID: 19660681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
